



ಭಾರತೀಯ ವಿಶಿಷ್ಟ ಗುರುತು ಪ್ರಾಧಿಕಾರ

ಭಾರತ ಸರ್ಕಾರ

Unique Identification Authority of India


Government of India

ನೋಂದಾವಣೆ ಕ್ರಮ ಸಂಖ್ಯೆ / Enrollment No.: 2086/10260/01524

ದೇವಪ್ಪ ದಾಸರ್ Devappa Dasar S/O Kanakappa Dasar Muddebihal Taluk Gotakandi Bhantnur Bhantanur (tkt) Muddebihal Bijapur Karnataka 586214 8867761958

Ref: 2995 / 23M / 242565 / 242628 / P





ನಿಮ್ಮ ಆಧಾರ್ ಸಂಖ್ಯೆ / Your Aadhaar No. :

9172 8575 8108

ನನ್ನ ಆಧಾರ್, ನನ್ನ ಗುರುತು



ಭಾರತ ಸರ್ಕಾರ

Government of India _ ದೇವಪ್ಪ ದಾಸರ್



Devappa Dasar ಜನ್ಮ ದಿನಾಂಕ / DOB : 20/06/1979 ಪುರುಪ / Male



9172 8575 8108

 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

M N

Ref. Dr : MediWheel

Investigation HAEMATOLOGY	Observed Value	<u>Unit</u>	Biological Reference Interval
Complete Blood Count With - ESR			
Haemoglobin (EDTA Blood/Spectrophotometry)	15.6	g/dL	13.5 - 18.0
Packed Cell Volume(PCV)/Haematocrit (EDTA Blood/Derived from Impedance)	47.1	%	42 - 52
RBC Count (EDTA Blood/Impedance Variation)	5.86	mill/cu.mm	4.7 - 6.0
Mean Corpuscular Volume(MCV) (EDTA Blood/Derived from Impedance)	80.0	fL	78 - 100
Mean Corpuscular Haemoglobin(MCH) (EDTA Blood/Derived from Impedance)	26.6	pg	27 - 32
Mean Corpuscular Haemoglobin concentration(MCHC) (EDTA Blood/Derived from Impedance)	33.2	g/dL	32 - 36
RDW-CV (EDTA Blood/Derived from Impedance)	15.5	%	11.5 - 16.0
RDW-SD (EDTA Blood/Derived from Impedance)	43.40	fL	39 - 46
Total Leukocyte Count (TC) (EDTA Blood/Impedance Variation)	5300	cells/cu.mm	4000 - 11000
Neutrophils (EDTA Blood/Impedance Variation & Flow Cytometry)	44.6	%	40 - 75
Lymphocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	44.8	%	20 - 45
Eosinophils (EDTA Blood/Impedance Variation & Flow Cytometry)	2.3	%	01 - 06





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

MEDALL

Type : OP

Printed On : 16/03/2022 7:53 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Monocytes (EDTA Blood/Impedance Variation & Flow Cytometry)	7.7	%	01 - 10
Basophils (EDTA Blood/Impedance Variation & Flow Cytometry)	0.6	%	00 - 02
Absolute Neutrophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.36	10^3 / µl	1.5 - 6.6
Absolute Lymphocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	2.37	10^3 / μl	1.5 - 3.5
Absolute Eosinophil Count (AEC) (EDTA Blood/Impedance Variation & Flow Cytometry)	0.12	10^3 / μl	0.04 - 0.44
Absolute Monocyte Count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.41	10^3 / μl	< 1.0
Absolute Basophil count (EDTA Blood/Impedance Variation & Flow Cytometry)	0.03	10^3 / μl	< 0.2
Platelet Count (EDTA Blood/Impedance Variation)	150	10^3 / μl	150 - 450
MPV (EDTA Blood/Derived from Impedance)	10.9	fL	7.9 - 13.7
PCT (EDTA Blood/Automated Blood cell Counter)	0.16	%	0.18 - 0.28
ESR (Erythrocyte Sedimentation Rate) (EDTA Blood/Modified Westergren)	2	mm/hr	< 15





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

MEDALL

Type : OP

Printed On: 16/03/2022 7:53 PM

Ref. Dr : MediWheel

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> Reference Interval
BIOCHEMISTRY			
Liver Function Test			
Bilirubin(Total) (Serum/Diazotized Sulfanilic Acid)	0.7	mg/dL	0.1 - 1.2
Bilirubin(Direct) (Serum/Diazotized Sulfanilic Acid)	0.2	mg/dL	0.0 - 0.3
Bilirubin(Indirect) (Serum/Derived)	0.5	mg/dL	0.1 - 1.0
Total Protein (Serum/Biuret)	7.2	gm/dL	6.0 - 8.0
Albumin (Serum/Bromocresol green)	4.5	gm/dL	3.5 - 5.2
Globulin (Serum/ <i>Derived</i>)	2.7	gm/dL	2.3 - 3.6
A : G Ratio (Serum/ <i>Derived</i>)	1.7		1.1 - 2.2
SGOT/AST (Aspartate Aminotransferase) (Serum/IFCC Kinetic)	26	U/L	5 - 40
SGPT/ALT (Alanine Aminotransferase) (Serum/IFCC / Kinetic)	34	U/L	5 - 41
Alkaline Phosphatase (SAP) (Serum/IFCC Kinetic)	65	U/L	53 - 128
GGT(Gamma Glutamyl Transpeptidase) (Serum/SZASZ standarised IFCC)	19	U/L	< 55





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

PM

Type : OP Printed On : 16/03/2022 7:53 PM

Ref. Dr : MediWheel

IVICE	766	

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<u>Lipid Profile</u>			
Cholesterol Total (Serum/Cholesterol oxidase/Peroxidase)	136	mg/dL	Optimal: < 200 Borderline: 200 - 239 High Risk: >= 240
Triglycerides (Serum/Glycerol phosphate oxidase / peroxidase)	75	mg/dL	Optimal: < 150 Borderline: 150 - 199 High: 200 - 499 Very High: >= 500

INTERPRETATION: The reference ranges are based on fasting condition. Triglyceride levels change drastically in response to food, increasing as much as 5 to 10 times the fasting levels, just a few hours after eating. Fasting triglyceride levels show considerable diurnal variation too. There is evidence recommending triglycerides estimation in non-fasting condition for evaluating the risk of heart disease and screening for metabolic syndrome, as non-fasting sample is more representative of the "usual" circulating level of triglycerides during most part of the day.

HDL Cholesterol (Serum/Immunoinhibition)	34	mg/dL	Optimal(Negative Risk Factor): >= 60 Borderline: 40 - 59 High Risk: < 40
LDL Cholesterol (Serum/Calculated)	87	mg/dL	Optimal: < 100 Above Optimal: 100 - 129 Borderline: 130 - 159 High: 160 - 189 Very High: >=190
VLDL Cholesterol (Serum/Calculated)	15	mg/dL	< 30
Non HDL Cholesterol (Serum/Calculated)	102.0	mg/dL	Optimal: < 130 Above Optimal: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very High: >= 220

INTERPRETATION: 1. Non-HDL Cholesterol is now proven to be a better cardiovascular risk marker than LDL Cholesterol. 2. It is the sum of all potentially atherogenic proteins including LDL, IDL, VLDL and chylomicrons and it is the "new bad cholesterol" and is a co-primary target for cholesterol lowering therapy.





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

Type: OP **Printed On**: 16/03/2022 7:53 PM

Ref. Dr : MediWheel



Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Total Cholesterol/HDL Cholesterol Ratio (Serum/Calculated)	4		Optimal: < 3.3 Low Risk: 3.4 - 4.4 Average Risk: 4.5 - 7.1 Moderate Risk: 7.2 - 11.0 High Risk: > 11.0
Triglyceride/HDL Cholesterol Ratio (TG/HDL) (Serum/Calculated)	2.2		Optimal: < 2.5 Mild to moderate risk: 2.5 - 5.0 High Risk: > 5.0
LDL/HDL Cholesterol Ratio (Serum/Calculated)	2.6		Optimal: 0.5 - 3.0 Borderline: 3.1 - 6.0 High Risk: > 6.0





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

MEDALL

Type : OP Printed On : 16/03/2022 7:53 PM

Ref. Dr : MediWheel

Investigation	Observed <u>Value</u>	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Glycosylated Haemoglobin (HbA1c)			
HbA1C (Whole Blood/ <i>HPLC</i>)	5.8	%	Normal: 4.5 - 5.6 Prediabetes: 5.7 - 6.4 Diabetic: >= 6.5

INTERPRETATION: If Diabetes - Good control: 6.1 - 7.0 %, Fair control: 7.1 - 8.0 %, Poor control >= 8.1 %

Estimated Average Glucose 119.76 mg/dL

(Whole Blood)

INTERPRETATION: Comments

HbA1c provides an index of Average Blood Glucose levels over the past 8 - 12 weeks and is a much better indicator of long term glycemic control as compared to blood and urinary glucose determinations.

Conditions that prolong RBC life span like Iron deficiency anemia, Vitamin B12 & Folate deficiency,

hypertriglyceridemia,hyperbilirubinemia,Drugs, Alcohol, Lead Poisoning, Asplenia can give falsely elevated HbAlC values. Conditions that shorten RBC survival like acute or chronic blood loss, hemolytic anemia, Hemoglobinopathies, Splenomegaly,Vitamin E ingestion, Pregnancy, End stage Renal disease can cause falsely low HbAlc.





PID No. : MED111017511 Register On : 12/03/2022 10:45 AM : 922015934 SID No. Collection On : 12/03/2022 11:01 AM Age / Sex : 42 Year(s) / Male

Report On : 13/03/2022 2:10 PM

: OP **Type** : 16/03/2022 7:53 PM **Printed On**

Ref. Dr : MediWheel



<u>Investigation</u>	<u>Observed</u>	<u>Unit</u>	<u>Biological</u>
	<u>Value</u>		Reference Interval

IMMUNOASSAY

THYROID PROFILE / TFT

T3 (Triiodothyronine) - Total 1.32 ng/mL 0.7 - 2.04

(Serum/CMIA)

INTERPRETATION:

Comment:

Total T3 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T3 is recommended as it is Metabolically active.

T4 (Thyroxine) - Total 8.00 4.2 - 12.0μg/dL

(Serum/CMIA)

INTERPRETATION:

Comment:

Total T4 variation can be seen in other condition like pregnancy, drugs, nephrosis etc. In such cases, Free T4 is recommended as it is Metabolically active.

2.09 0.35 - 5.50TSH (Thyroid Stimulating Hormone) μIU/mL

(Serum/Chemiluminescent Microparticle

Immunoassay(CMIA))

INTERPRETATION:

Reference range for cord blood - upto 20

1 st trimester: 0.1-2.5 2 nd trimester 0.2-3.0 3 rd trimester : 0.3-3.0

(Indian Thyroid Society Guidelines)

Comment:

- 1.TSH reference range during pregnancy depends on Iodine intake, TPO status, Serum HCG concentration, race, Ethnicity and BMI.
- 2.TSH Levels are subject to circadian variation, reaching peak levels between 2-4am and at a minimum between 6-10PM. The variation can be of the order of 50%, hence time of the day has influence on the measured serum TSH concentrations.
- 3. Values&lt 0.03 µIU/mL need to be clinically correlated due to presence of rare TSH variant in some individuals.



 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM



Ref. Dr : MediWheel

Investigation	<u>Observed</u>	<u>Unit</u>	<u>Biological</u>
-	<u>Value</u>		Reference Interval

D 1 37 11

CLINICAL PATHOLOGY

PHYSICAL EXAMINATION

Colour (Urine)	Pale Yellow		
Appearance (Urine)	Clear		Clear
Volume (Urine)	15	mL	
<u>CHEMICAL EXAMINATION(Automated-Urineanalyser)</u>			

pH	6.0	4.5 - 8.0
(Urine/AUTOMATED URINANALYSER)		

Specific Gravity 1.020 1.002 - 1.035

(Urine)

Ketones Negative Negative

(Urine)

Urobilinogen 0.2 0.2 - 1.0

(Urine/AUTOMATED URINANALYSER)

Blood Negative Negative

(Urine/AUTOMATED URINANALYSER)

Nitrite Negative Negative

(Urine/AUTOMATED URINANALYSER)

Bilirubin Negative Negative

(Urine/AUTOMATED URINANALYSER)

Protein Negative Negative

(Urine)

Glucose Negative Negative

(Urine)





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

Printed On

MEDALL

Ref. Dr : MediWheel

: OP

Type

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
Leukocytes (Urine) MICROSCOPY(URINE DEPOSITS)	Negative	leuco/uL	Negative
Pus Cells (Urine/Flow cytometry)	0-2	/hpf	3-5
Epithelial Cells (Urine)	0-2	/hpf	1-2
RBCs (Urine/Flow cytometry)	Nil	/hpf	2-3
Others (Urine)	Nil		Nil
Casts (Urine/Flow cytometry)	Nil	/hpf	0 - 1
Crystals (Urine)	Nil		NIL

: 16/03/2022 7:53 PM





 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

Printed On

MEDALL

Type : OP

Ref. Dr : MediWheel

16/03/2022 7:53 PM

Investigation	Observed Value	<u>Unit</u>	Biological Reference Interval
BIOCHEMISTRY			
BUN / Creatinine Ratio	11.6		6 - 22
Glucose Fasting (FBS) (Plasma - F/GOD - POD)	75	mg/dL	Normal: < 100 Pre Diabetic: 100 - 125 Diabetic: >= 126

INTERPRETATION: Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level.

Glucose Fasting - Urine	Negative		Negative
(Urine - F)			
Glucose Postprandial (PPBS)	93	mg/dL	70 - 140
(Plasma - PP/GOD - POD)			

INTERPRETATION:

Factors such as type, quantity and time of food intake, Physical activity, Psychological stress, and drugs can influence blood glucose level. Fasting blood glucose level may be higher than Postprandial glucose, because of physiological surge in Postprandial Insulin secretion, Insulin resistance, Exercise or Stress, Dawn Phenomenon, Somogyi Phenomenon, Anti- diabetic medication during treatment for Diabetes.

Glucose Postprandial - Urine (Urine - PP)	Negative		Negative		
Blood Urea Nitrogen (BUN) (Serum/Urease-GLDH)	14	mg/dL	7.0 - 21		
Creatinine (Serum/Jaffe Kinetic)	1.2	mg/dL	0.9 - 1.3		

INTERPRETATION: Elevated Creatinine values are encountered in increased muscle mass, severe dehydration, Pre-eclampsia, increased ingestion of cooked meat, consuming Protein/ Creatine supplements, Diabetic Ketoacidosis, prolonged fasting, renal dysfunction and drugs such as cefoxitin, cefazolin, ACE inhibitors, angiotensin II receptor antagonists, N-acetylcyteine, chemotherapeutic agent such as flucytosine etc.

Uric Acid 5.4 mg/dL 3.5 - 7.2 (Serum/*Uricase/Peroxidase*)





PID No. : MED111017511 Register On : 12/03/2022 10:45 AM : 922015934 SID No. Collection On : 12/03/2022 11:01 AM Age / Sex : 42 Year(s) / Male

Printed On

Report On : 13/03/2022 2:10 PM

: 16/03/2022 7:53 PM

: OP **Type**

Ref. Dr : MediWheel



Prostate: > 10.0

Investigation	Observed Value	<u>Unit</u>	<u>Biological</u> <u>Reference Interval</u>
<u>IMMUNOASSAY</u>			
Prostate specific antigen - Total(PSA) (Serum/Chemiluminescent Microparticle Immunoassay(CMIA))	0.514	ng/mL	Normal: 0.0 - 4.0 Inflammatory & Non Malignant conditions of Prostate & genitourinary system: 4.01 - 10.0 Suspicious of Malignant disease of

INTERPRETATION: Analytical sensitivity: 0.008 - 100 ng/mL

PSA is a tumor marker for screening of prostate cancer. Increased levels of PSA are associated with prostate cancer and benign conditions like bacterial infection, inflammation of prostate gland and benign hypertrophy of prostate/ benign prostatic hyperplasia (BPH).

Transient elevation of PSA levels are seen following digital rectal examination, rigorous physical activity like bicycle riding, ejaculation within 24 hours.

PSA levels tend to increase in all men as they age.

Clinical Utility of PSA:

- •In the early detection of Prostate cancer.
- •As an aid in discriminating between Prostate cancer and Benign Prostatic disease.
- •To detect cancer recurrence or disease progression.



 PID No.
 : MED111017511
 Register On
 : 12/03/2022 10:45 AM

 SID No.
 : 922015934
 Collection On
 : 12/03/2022 11:01 AM

 Age / Sex
 : 42 Year(s) / Male
 Report On
 : 13/03/2022 2:10 PM

Type: OP **Printed On**: 16/03/2022 7:53 PM

Ref. Dr : MediWheel

MEDALL

InvestigationObservedUnitBiologicalValueReference Interval

IMMUNOHAEMATOLOGY

BLOOD GROUPING AND Rh TYPING 'A' 'Positive'

 $(EDTA\ Blood Agglutination)$





APPROVED BY

-- End of Report --



Name	MR.DEVAPPA DASAR	ID	MED111017511
Age & Gender	42Y/MALE	Visit Date	12/03/2022
Ref Doctor	MediWheel		

ABDOMINO-PELVIC ULTRASONOGRAPHY

LIVER is normal in shape, size and has uniform echopattern. No evidence of focal lesion or intrahepatic biliary ductal dilatation. Hepatic and portal vein radicals are normal.

GALL BLADDER show normal shape and has clear contents. Gall bladder wall is of normal thickness.

CBD is of normal calibre.

PANCREAS has normal shape, size and uniform echopattern.

No evidence of ductal dilatation or calcification.

SPLEEN show normal shape, size and echopattern.

No demonstrable Para -aortic lymphadenopathy.

KIDNEYS move well with respiration and have normal shape, size and echopattern.

Cortico- medullary differentiations are well madeout.

No evidence of calculus or hydronephrosis.

The kidney measures as follows

	Bipolar length (cms)	Parenchymal thickness (cms)
Right Kidney	8.0	1.2
Left Kidney	8.6	1.4

URINARY BLADDER show normal shape and wall thickness.

It has clear contents. No evidence of diverticula.

PROSTATE shows normal shape, size and echopattern.

No evidence of ascites.

Impression: Essentially normal study

CONSULTANT RADIOLOGISTS:

DR. H. K. ANAND

DR. PRAJNA SHENOY

DR. MAHESH. M. S

DR. RADHA KRISHNA. A.

DR. HIMA BINDU.P

Hbp/so





Name	DEVAPPA DASAR	Customer ID	MED111017511
Age & Gender	42Y/M	Visit Date	Mar 12 2022 10:44AM
Ref Doctor	MediWheel		9

X-RAY CHEST PA VIEW

Bilateral lung fields appear normal.

Cardiac size is within normal limits.

Bilateral hilar regions appear normal.

Bilateral domes of diaphragm and costophrenic angles are normal.

Visualised bones and soft tissues appear normal.

Impression: Essentially normal study.

DR. H.K. ANAND

DR. POOJA B.P

DR. SHWETHA S


CONSULTANT RADIOLOGISTS

The same of the sa

DR. PRAJNA SHENOY



		Technician: MANJU						RECOVERY		PAERCISE	PRETEST	Phase Name		14:19:50	10 Mar 5090	ID: MED
P/N 2009828-020								Post	STAGE :	STAGE 1	SUPINE	Stage Name	Referred by: C/O MEDI WHEEL Test ind: IHD SCREENING		41years	XXXXXX
	CLUMAX DIAGNOSTICS							5:12	2:00 2:00	3:00 3:00	6:04	Time in Stage	1199		Male	TV.
Vit								* ;	;; }-	ب د ارد	1.0	Speed (mph)				
Vital Signs™		Ur						* , * ,	14 6	0.01	0.0	Grade (%)	IMP:STRESS TEST IS ## NEEDS CLINICAL *** DR.SRIDHAR	Comments: GOOD EF OO SIGNIFICANT ST.	Max HR: 153bpm Max BP: 140/70	PRICE TELOIT
		Unconfirmed				Intervention on K.M.C. N.	>	1.0	3	-1 # P	1.7	WorkLoad (METS)	EST IS NEGAT NICAL CORRE	GOOD EFFORT TO CHAN A ARRHYTHMIAS.	85% of max	141
						K.M.C. No. 27248		95	<u> </u>	197	<u> </u>	(bpm)	TIVE FOR INI LATION FOR MD,DM,FICC.	RT TOLERANCI HANGES SEEN IAS.	predicted 179bpm Maximum workload:	
PRINTED IN U.S.A.	MA					IDMAR L Incardiologis		(130 70	190/70	110/70	BP C	NEGATIVE FOR INDUCIBLE ISCHEMIA. CORRELATION FOR FURTHER MANAGEMENT L MD,DM,FICC. CARDIOLOGIST ***	E.NORMAL HR DURING EXE		
	MAC55 010Bsp1					*(10	Or X		10 kg	က် မိုင် ၁၈ မိုင် ၁၈ တ	89 •	RPP (x100)	HEMIA MANAGEMENT : GIST ***	Comments: GOOD EFFORT TOLERANCE NORMAL HR AND BP RESPONSE. NO SIGNIFICANT ST-T CHANGES SEEN DURING EXERCISE & RECOVERY NO ANGINA/ARRHYTHMIAS.	10.1METS	
						Q37	<u></u>						#	NSE. VERY	23.0 mm/s 10.0 mm/mV 100hz	TATTE VEG



Customer Name	Devappa. D	Customer ID	1110/7511
Age & Gender	Apr) NO,	Visit Date	12/03/22

Eye Screening

With spectacles / without spectacles (strike out whichever is not applicable)

Left Eye Right Eye Near Vision Distance Vision Colour Vision Noma

Observation / Comments:

Ny Glasser

Rand. No. 11201